The label’s dysgeusia line, and what is missing
Foundayo™ is a once-daily tablet containing orforglipron, which the trial reports describe as a small-molecule GLP-1 receptor agonist that is not a peptide [9]. Its label counts side effects from two placebo-controlled weight trials of up to 72 weeks, known as ATTAIN-1 and ATTAIN-2 [1]. Taste is not among the reactions in Table 1, which needs a rate of at least 5%. It appears lower down, in a short paragraph of other reactions [1].
| Source | Entry | Comparison |
|---|---|---|
| US Prescribing Information, section 6.1 [1] | Dysgeusia 0.9% | Placebo 0.3% (Trials 1 and 2 pooled) |
| US Prescribing Information, section 6.1 [1] | Dysesthesia, a separate entry for abnormal sensations: 0.3% on 9 mg and 1% on 17.2 mg | Placebo 0.1%; not a taste term |
| US Medication Guide [2] | Taste not mentioned | Patient-facing list |
| European Medicines Agency [3] | Committee opinion adopted 15 October 2026; no product information published yet | No EU frequency band available |
| Health Canada [4] | Not found in the Drug Product Database | No Canadian monograph to compare |
Smaller trials that list every event
Some orforglipron trials posted every adverse event on ClinicalTrials.gov, however rare, rather than only those above 5%. These were mainly diabetes trials using trial doses, not the strengths sold as Foundayo™, and the numbers in each group are small.
| Trial [source] | Comparison group | Orforglipron groups |
|---|---|---|
| ACHIEVE-1, early type 2 diabetes, 40 weeks [5] | Placebo 0 of 138 | Dysgeusia 1 of 137 (12 mg); taste disorder 1 of 143 (3 mg) |
| ACHIEVE-5, type 2 diabetes on insulin glargine, 40 weeks [7] | Placebo 0 of 140 | Dysgeusia 1 of 137 (3 mg) and 2 of 132 (12 mg) |
| ATTAIN-J, Japanese adults with obesity, 72 weeks [6] | Placebo 0 of 60 | Dysgeusia 1 of 61 (6 mg) and 3 of 60 (36 mg) |
| ACHIEVE-J, Japanese adults with type 2 diabetes, 52 weeks, no comparator [8] | None: every group took orforglipron | Taste disorder 1 to 3 per group of about 133; dysgeusia 1 of 132 |
How much weight to give these figures
- Across the placebo-controlled studies, taste events were few on orforglipron and absent on placebo. That points in one direction, but counts of one to three people cannot show how often taste changes really happen.
- There is no dose pattern to speak of. The 3 of 60 on the highest dose in ATTAIN-J is the largest share, yet in ACHIEVE-1 and ACHIEVE-5 the highest dose had no taste events at all [5][6][7].
- Registry entries do not say what the change felt like, when it began or whether it faded.
- ACHIEVE-J had no comparison group, so its figures show only that taste complaints were reported, not that they exceeded what would happen anyway [8].
Taste, smell and food preference
The label offers no mechanism for dysgeusia. What it does describe is a change in eating: the tablet lowers food intake, most likely by reducing appetite, and slows stomach emptying, most of all after the first dose [1]. Finding a dish less appealing because you are full sooner is not the same as tasting it differently, and keeping the two apart helps when you describe the problem.
NIDCD, part of the NIH, explains that flavour combines taste with smell, and that most people who believe they have lost their sense of taste actually have a smell problem [11]. It describes dysgeusia as a lingering foul, salty, rancid or metallic taste [11]. Noting which of these fits, and whether smell has changed too, gives a clinician much more to work with than “food tastes off”.
Causes that have nothing to do with the tablet
MedlinePlus and NIDCD list a long set of possible causes [10][11]:
- Colds, flu and other viral infections, sinus or nasal infections, nasal polyps and sore throats.
- A dry mouth, swollen gums, poor oral hygiene and other dental problems.
- Smoking, especially pipes and cigars.
- Medicines such as some antibiotics, including clarithromycin, antihistamines, lithium and some thyroid and cancer medicines.
- Low vitamin B12 or zinc, head injury, and ear, nose or throat surgery.
- Age: the sense of taste often weakens after 60, salty and sweet first.
What the guidance suggests
For taste loss after a cold or flu, MedlinePlus says normal taste usually returns once the illness passes, and it advises stopping smoking [10]. NIDCD suggests making food more interesting with colour, texture, herbs and spices, while avoiding extra sugar or salt, and warns that people sometimes over-salt or over-sweeten when taste is weak [11]. That matters for people with diabetes or high blood pressure: in the trials behind the label, about half of participants had high blood pressure and almost a third had type 2 diabetes [1].
If a medicine seems to be the cause, NIDCD notes that changing it may help but says not to stop any medicine unless your doctor tells you to [11]. Because Foundayo™ is swallowed whole and not chewed, the tablet itself spends little time in the mouth; the label does not discuss whether this affects taste [1].
Points specific to Foundayo™
The tablet is taken once a day with or without food, and the dose is raised no sooner than every 30 days, from 0.8 mg up to a possible 17.2 mg [1]. Writing down the date a taste change started, and the dose you were on, lets your prescriber see whether it followed a step.
The label lists the tablet’s inactive ingredients, including copovidone, magnesium stearate and a film coating with titanium dioxide and iron oxides [1]. It does not link any of them to taste, so this is background for a pharmacist conversation, not an explanation.
Foundayo™ is a trademark of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Eli Lilly and Company.
When to get help
The signs and contact information below come from this article’s sourced guidance.
Emergency
- Your throat, tongue, lips or face start to swell, or breathing or swallowing becomes hard
Contact: Stop the tablet and get emergency help
Foundayo™ Medication Guide [2]